Emerging Flt3 kinase inhibitors in the treatment of leukaemia

Expert Opinion on Emerging Drugs
Lara TickenbrockHubert Serve

Abstract

Acute myeloid leukaemia (AML) is characterised by the infiltration of the bone marrow with highly proliferative leukaemic cells that stop to differentiate at different stages of myeloid development and carry survival advantages. Conventionally, AML is treated with aggressive cytotoxic therapy, in eligible patients followed by allogeneic bone marrow transplantation. However, despite this aggressive treatment, many patients relapse and eventually die from the disease. Activating mutations in the coding sequence of the receptor tyrosine kinase Flt3 are found in leukaemic blasts from approximately 30% of AML patients. The mutations have been described to severely alter the signalling properties of this receptor and to have transforming activity in cell-line models and in primary mouse bone marrow. The prognosis of patients harbouring the most common Flt3 mutations tends to be worse than that of comparable patients without the mutations. Thus, Flt3 seems a promising target for therapeutic intervention. Several small molecules that inhibit Flt3 kinase activity are being evaluated for the treatment of AML in clinical trials. This review article discusses the signal transduction and biological function of Flt3 and its mutations in norm...Continue Reading

References

Jan 18, 1994·Proceedings of the National Academy of Sciences of the United States of America·D SmallA M Gewirtz
Aug 26, 1998·Cell·A Weiss, J Schlessinger
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D J PropperC Twelves
Jul 10, 2001·British Journal of Haematology·F M Abu-DuhierJ T Reilly
Jun 4, 2002·Current Opinion in Hematology·D Gary Gilliland, James D Griffin
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Louise M KellyD Gary Gilliland
Jul 19, 2002·Cancer Cell·D Gary Gilliland, Martin S Tallman
Jul 20, 2002·Blood·Beatrice U MuellerDaniel G Tenen
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Dec 14, 2002·Blood·Mustafa BenekliMeir Wetzler
Apr 15, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Mohammad Hasan SheikhhaJohn Ahman Liu Yin
Apr 30, 2003·Nature·Tannishtha ReyaIrving L Weissman

❮ Previous
Next ❯

Citations

Jan 30, 2010·Leukemia·E VoissetP De Sepulveda
Apr 6, 2007·Biological & Pharmaceutical Bulletin·Zhuan-Hua WangLei Zhu
Feb 24, 2015·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Oytun ErbasAltug Yavasoglu
Mar 3, 2009·Expert Opinion on Emerging Drugs·Luigi Naldi, Giovanna Raho
Jan 24, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·S Haihua Chu, Donald Small
Jan 11, 2007·Bioorganic & Medicinal Chemistry·Siavosh MahboobiStefan Dove
Nov 20, 2008·British Journal of Haematology·Frank-D Böhmer, Andrea Uecker
Nov 13, 2007·Critical Reviews in Oncology/hematology·Felicetto FerraraFranco Leoni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.